Goal to end AIDS by 2030 'more off-track' after Trump cuts, UNAIDS head says
By Tim Cocks
JOHANNESBURG (Reuters) -Donald Trump's cuts to HIV/AIDS programmes will further derail an already faltering plan to end the disease as a public health threat by 2030, UNAIDS Executive Director Winnie Byanyima said on Friday.
With 1.3 million new infections in 2023, according to the latest data, the world was already "off track," Byanyima told journalists in South Africa, a country with the world's largest number of people living with HIV, at 8 million.
"Less funding means we will get more and more off-track," she said in the main city of Johannesburg, after meeting President Cyril Ramaphosa to discuss Africa's HIV/AIDS strategy in light of the U.S. president slashing billions of dollars in foreign aid in February.
"We don't know yet what that impact will be, but impact there will be: ... already you see in several countries a drop in the number of people going to clinics," Byanyima said.
Before the cuts, prevention programmes had brought down new infections, she said, but they were "not coming down fast enough to reach our target of 2023."
Now, with the shuttering of community prevention clinics across Africa, infections would surely rise, though it wasn't clear yet by how much, she said.
The administration's decision to axe swaths of U.S. foreign aid has disrupted the supply of life-saving HIV treatments, with some countries facing potentially running out. In South Africa, about a fifth of whose HIV budget was U.S.-funded, testing and monitoring of HIV patients is already falling.
Byanyima said even poor, indebted countries were managing to plug funding gaps, but called on other rich nations to step in.
"We're saying to the donors: this is one of the diseases ... without a cure, without a vaccine, yet we're seeing progress," she said. "If you've got a good success story, why drop it ... before you end it?"
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
After U.S. cuts billions, East African countries steps up to plug budget gaps
Finance ministers across East Africa have increased health spending following U.S. President Donald Trump's sudden withdrawal of billions of dollars in aid earlier this year. East African finance ministers have increased health expenditure due to a significant withdrawal of U.S. aid. Uganda announced an allocation of $32 million for antiretroviral medication to address the issue. Tanzania committed $31.8 million to cover immediate funding gaps resulting from aid withdrawal. Finance ministers across East Africa have increased health spending following U.S. President Donald Trump's sudden withdrawal of billions of dollars in aid earlier this year. The move, along with his protectionist policies that sparked tit-for-tat trade wars, sent shockwaves around the world, but nowhere has the impact been more deeply felt than in Africa. Already, tens of thousands of healthcare workers across the continent have lost their jobs. And for many of the 17 million Africans living with HIV, two-thirds of all cases globally, access to life-saving treatment is now slipping out of reach, according to Bloomberg. Sub-Saharan Africa remains at the heart of the global HIV crisis. According to Statista, millions across the region live with the virus, with thousands more newly infected each year, a stark reminder of the urgent need for sustained support and investment. Emergency budget plans Health advocates like Vincent Bagambe, Planning Director at the Uganda AIDS Commission, have raised the alarm that without swift action, recent funding cuts could undermine years of progress in reducing new HIV infections and curbing AIDS-related deaths. In response, Uganda, Tanzania, and Kenya announced new plans in their 2025–26 budgets, delivered on Thursday, to fill the growing funding gap. The U.S. had allocated $200 million in aid for these countries this year, support that has now been withdrawn. Uganda, often praised as one of Africa's success stories in tackling HIV and AIDS, is stepping up its response. The country plans to spend an additional 116.8 billion shillings ($32 million) on antiretroviral medication, Finance Minister Matia Kasaija announced. Uganda currently has about 1.5 million people living with HIV, with a national prevalence rate of 5.1%, according to the Uganda AIDS Commission. In 2024, it received $194 million in HIV/AIDS assistance from the United States, the fifth-highest allocation globally, according to Statista. Next door in Tanzania, which received $166 million in U.S. HIV/AIDS assistance in 2024, the government has already disbursed over 82 billion shillings ($31.8 million) to help cover funding shortfalls caused by the abrupt withdrawal, according to Finance Minister Mwigulu Nchemba. Kenya, East Africa's biggest economy and a recipient of $187 million in U.S. aid, is also responding. Treasury Secretary John Mbadi announced plans to allocate 17.3 billion shillings ($134 million) to the Global Fund, which supports efforts to combat HIV/AIDS, malaria, and tuberculosis. Another 4.6 billion shillings will go toward vaccines and immunization programs.
CBS News
6 hours ago
- CBS News
Chicago doctor Cathy Creticos has been at the forefront of HIV/AIDS research and treatment for decades
Dr. Cathy Creticos with the Howard Brown Health Center has been at the forefront of HIV and AIDS research and treatment for decades, saving countless lives. She has also been an ally to the LGBTQ+ community and, according to her patients, a friend. They call her Dr. C, with love, and she says the feeling is mutual. "She's in that list of people I'm thankful for every day of my life," said Madrid St. Angelo. "She literally has been a lifeline for me." St. Angelo is an actor, artistic director and instructor, and he's been living with HIV/AIDS for almost 30 years. "I met Dr. C in 1992 when I was very, very sick and since that time she literally has guided me every step of the way on my wellness journey," he said. Creticos has headed up the team at Chicago's Howard Brown Health Center since 1995, but she has been at the forefront of HIV/AIDS research and treatment since the very beginning. Dr. Creticos' father was a physician whose name is on the cancer center at Illinois Masonic Medical Center, but she didn't want to be a doctor originally. "I had an awakening, I heard a voice kind of thing, it just all gelled for me," she said. "Being a physician was something I could do to really contribute in a more concrete, meaningful way." After attending medical school at the University of Chicago, she specialized in infectious disease at the University of Illinois, a field she found intriguing. "You actually can cure most infectious diseases, many infectious diseases," Creticos said. "Then we ran head first into HIV and that was the opposite what I thought infectious disease was going to be about." It was 1984, and no one even had a name for the mysterious, complicated virus that devastated the body's immune system, taking lives at rapid speed. Creticos became a part of a team working on the very first HIV medication trial testing AZT, the first drug approved to treat the virus. "It was very interesting," she said. "My patients were just amazing people. So resilient, so full of hope and courage, and determination to still live life despite having a very difficult diagnosis." As breakthroughs in treatment slowly came, so did joy. "I literally saw people who were comatose and even unable to raise their head off the bed returning to a full life," Creticos said. "That type of transformation was an amazing experience. I loved being part of that." But barriers to care remain, even today. "Probably one of the biggest barriers is our messed-up health system. Even patients who want to take their medicine and do it every day, their job changes, their insurance changes and prior authorization changes, so the meds they're taking are no longer authorized," she said. And the stigma around HIV/AIDS persists as well. "It still is a very pervasive, persistent problem," she said. "HIV is a virus. It can infect anybody. Anybody. And there's nothing particular about a certain type of people, that's just hogwash." Creticos said that's why education is crucial. "People who are sexually active, who don't consider themselves in a category at risk for HIV are not open to the idea of pre-exposure prophylaxes," she said. Those are the "PreP" medications that block HIV from taking hold and spreading. While Creticos and her team know an HIV vaccine may be a way's off, there is hope in the future. "There are some really impressive results in terms of getting the patient's immune system required to control the virus without medication," she said. But she said no treatment is complete without the personal touch and the compassion patients deserve. "She's a friend, she's a mentor, she's an inspiration," St. Angelo said. "I've told her many times I would not be here today if it weren't for you. I thank you from the bottom of my heart." Creticos said she first wanted to be a humanities professor, but she's so happy she heard the voice that told her to change her plans. Do you know someone a person or place that brings you joy? We want to share your story. Send us your "Eye on Chicago" ideas using the form below (or clicking here):
Yahoo
10 hours ago
- Yahoo
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after dismissing all 17 existing advisers. Kennedy justified the overhaul to 're-establish public confidence in vaccine science,' claiming, without providing specific evidence, that prior Biden-appointed members had conflicts of interest. The new eight-member committee represents the minimum allowed under ACIP's founding charter. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Martin Kulldorff, a biostatistician and epidemiologist, was among eight individuals selected by Kennedy to join the Advisory Committee on Immunization Practices (ACIP). Kulldorff has been an outspoken critic of COVID-19 lockdowns and vaccine mandates. His appointment has also raised questions due to his paid involvement in litigation against a major vaccine manufacturer, according to Reuters. Citing court records, Reuters notes that Kulldorff served as an expert witness in lawsuits against Merck & Co Inc (NYSE:MRK) over its Gardasil vaccine, which is used to prevent cancers caused by the human papillomavirus (HPV). The plaintiff accused the pharmaceutical company of not properly disclosing the vaccine's risks. Gardasil was approved in the U.S. in 2006 after going through clinical trials to prove its safety and a deposition in October, Kulldorff acknowledged that he had been paid $400 an hour for his work on the case and had billed approximately $33,000 through September. He also received a $4,000 retainer in connection with the North Carolina lawsuit, which was part of a broader legal effort encompassing about 200 related cases. In March, a federal judge ruled in favor of Merck in that particular case. Kulldorff's paid role as a litigation consultant could conflict with ACIP's established rules. According to the committee's guidelines, members are prohibited from serving as paid expert witnesses or litigation consultants in cases involving vaccine manufacturers while actively serving on the panel. Gardasil/Gardasil 9 sales declined 41% to $1.33 billion in the first quarter of 2025, primarily due to lower demand in China, partially offset by higher demand in most international regions, particularly in Japan, and higher pricing and demand in the U.S. Excluding China, sales grew 14%, or 16%, excluding the impact of foreign exchange. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit originally appeared on Sign in to access your portfolio
